NADMED Ltd.

We are excited to announce NADMED Ltd. as a Tier 5 Sponsor of the 11th Aging Research & Drug Discovery Meeting. NADMED has brought to the market the first accurate, fast, and scalable NAD measuring technology. This technology offers accurate measurement of all four forms of NAD and glutathione from all biological samples, including blood. It is available in both kit format and as a service. With a global reach, NADMED serves a wide range of customers, including CROs, pharmaceutical companies, research institutions, clinics, and laboratories. Some of the notable clients include National Institutes of Health (NIH), Synlab, Clene Nanomedicine, and Newcastle University. The growing interest in understanding the role of NADs in longevity underscores the relevance of NADMED's technology. As essential components in the aging process, NADs play a crucial role in maintaining mitochondrial health. #ARDD2024 will feature a dynamic mix of academic institutions, clinicians, industry leaders, and pharmaceutical companies, fostering rich dialogues and unveiling new research in the field of aging. Mark your calendars for August 26-30, 2024 and register now at agingpharma.org https://lnkd.in/gzdY8JHv #ARDD2024 #DrugDiscovery #AgingResearch

Last week, Clene Nanomedicine, Inc.'s Vice President of Translational Medicine Karen S. Ho, PhD was invited to present and participate in a Workshop on Mitochondrial Biomarkers for Parkinson’s Disease at The Michael J. Fox Foundation for Parkinson's Research. This highly collaborative and educational experience encouraged researchers from diverse backgrounds to exchange insights and ideas on identifying and developing mitochondrial biomarkers for Parkinson's Disease. Thanks to the organizers for this opportunity to contribute and learn alongside such esteemed colleagues as we aim to advance #ParkinsonsResearch.